New targets and approaches are under investigation for the treatment of nonmuscle invasive bladder cancer (NMIBC). Preclinical data suggest cyclooxygenase-2 (COX-2) as a promising target. Celecoxib, a COX-2 selective inhibitor, inhibits tumor development and enhances survival, both in vitro and in vivo models of bladder cancer. Therefore, we conducted a pilot study of celecoxib to prevent recurrence in patients with intermediate risk NMIBC.
Pagliarulo, V., Ancona, P., Martines, I., Spadavecchia, R., DI STASI, S.m., Alba, S., et al. (2015). Celecoxib for the prevention of nonmuscle invasive bladder cancer: Results from a matched control study. THERAPEUTIC ADVANCES IN UROLOGY, 7(6), 303-311 [10.1177/1756287215599695].
Celecoxib for the prevention of nonmuscle invasive bladder cancer: Results from a matched control study
DI STASI, SAVINO MAURO;
2015-12-01
Abstract
New targets and approaches are under investigation for the treatment of nonmuscle invasive bladder cancer (NMIBC). Preclinical data suggest cyclooxygenase-2 (COX-2) as a promising target. Celecoxib, a COX-2 selective inhibitor, inhibits tumor development and enhances survival, both in vitro and in vivo models of bladder cancer. Therefore, we conducted a pilot study of celecoxib to prevent recurrence in patients with intermediate risk NMIBC.File | Dimensione | Formato | |
---|---|---|---|
THER ADV UROL 2015 (1).pdf
accesso aperto
Licenza:
Non specificato
Dimensione
504.57 kB
Formato
Adobe PDF
|
504.57 kB | Adobe PDF | Visualizza/Apri |
THER ADV UROL 2015 (1).pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
504.57 kB
Formato
Adobe PDF
|
504.57 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.